Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078420 | 1.00 | ELANE (0.62) | ELANETP53SMN1; SMN2FAAHCES1 | |
| SCHEMBL12777984 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2077538 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL13039558 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2078449 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL12844728 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL12777968 | 0.93 | ELANE (0.72) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2076871 | 0.91 | ELANE (0.74) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL10656661 | 0.87 | ELANE (0.76) | ELANETP53SMN1; SMN2MAPTMEN1 | |
| SCHEMBL2076618 | 0.85 | ELANE (0.47) | ELANETP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| US-8372430-B2 | comprises stiffening agents for ameliorating side effects associated with adminstration of lipase inhibitors (anal leakage of undigested fat or oil); for treatment of diabetes | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| EP-1572240-B1 | COMPOSITIONS, METHODS, AND KITS USEFUL FOR THE ALLEVIATION OF GASTROINTESTINAL SIDE EFFECTS OF LIPASE INHIBITORS | PROCTER & GAMBLE (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-7825113-B2 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2010-11-02 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080075688-A1 | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body | THE PROCTER & GAMBLE COMPANY | 2008-03-27 | — | — | US | disclosed |
| EP-1572240-A1 | COMPOSITIONS, METHODS, AND KITS USEFUL FOR THE ALLEVIATION OF GASTROINTESTINAL SIDE EFFECTS OF LIPASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004060401-A1 | COMPOSITIONS, METHODS, AND KITS USEFUL FOR THE ALLEVIATION OF GASTROINTESTINAL SIDE EFFECTS OF LIPASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040126424-A1 | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects | JANDACEK RONALD JAMES (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040091450-A1 | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body | THE PROCTER & GAMBLE COMPANY | 2004-05-13 | — | — | US | disclosed |
| US-6624161-B2 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | LPL, LIPE, PNLIP | ELANE 419/4885TP53 4377/4885SMN1; SMN2 3883/4885 |
| US-20080075688-A1 | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body | LIPA, PNLIP, CEL | ELANE 73/4885TP53 3569/4885SMN1; SMN2 3553/4885 |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | CYP1B1, CYP4X1, ACOX1 | ELANE 1015/4885TP53 4864/4885SMN1; SMN2 3659/4885 |
| US-20040126424-A1 | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects | PNLIP, LIPC, LIPA | ELANE 260/4885TP53 4285/4885SMN1; SMN2 2073/4885 |
| US-20040091450-A1 | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body | LIPA, PNLIP, CEL | ELANE 73/4885TP53 3569/4885SMN1; SMN2 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.